Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis…
The approval could present a major challenge to Ocaliva (obeticholic acid), which was until recently the sole approved drug for…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ocaliva
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData
The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029